The SCCC-Upstate is a merger of two successful legacy CCOPs known as Southeast Cancer Control Consortium, Inc. (SCCC) and Upstate Carolina (hereafter the Consortium) comprised of 23 components and 63 sub-components, located in a five-state area of the Southeast US (GA, NC, SC, TN, and VA) with a nonclinical Administrative Office (AO) in Winston-Salem, NC. The Consortium eliminates a critical barrier by supplying service to the rural southeastern area. The AO provides expertise, regulatory support, training, education, and principal investigators to enable small rural community hospitals, private practices, and solo practitioners the ability to provide clinical trials to ther patients. With this structure, rural centers will be able to translate academic-generated concepts to the real world. Economic constraints prohibit most hospitals and private practices from allocating the required resources to conduct research independently. This structure has been successful in supporting rural communities for the past 30 years. This was the vision of Charles L Spurr, MD that has been carried on by Drs. Atkins and Bearden to make clinical trials available in the patient's home community. Each component has a responsible investigator and coordinator to organize and promote clinical research participation. Over 232 investigators and 140 research staff located at 86 treatment centers are involved in the delivery of research in a variety of community settings. The vast geographical area improves the opportunity to increase access of NCI-sponsored clinical trials. The long-term objectives are to: 1) provide cutting edge clinical trials;2) implement programs to enhance cancer care delivery;3) build on existing relationships and establish new collaborations;and 4) actively enroll participants to clinical trials. The catchment area of the components is over 9.5 million, with diverse demographics including a significant African American population. NCI support of this grant will allow restricted federal dollars to be maximized over a vast rural geographic area reaching rural and medically underserved populations.

Public Health Relevance

Advances in oncology can only be made through the execution of well-designed clinical trials, and these advances will lead to improved survival and public health. This 23-member Consortium has the strength and capability to contribute to this outcome. Through the combined strength of this consortium, clinical trials are accessible to small, rural, medically underserved Appalachia communities of the Southeast.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Xie, Heng
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Southeast Cancer Control Consortium
United States
Zip Code
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32
Ben-Josef, Edgar; Guthrie, Katherine A; El-Khoueiry, Anthony B et al. (2015) SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol 33:2617-22
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373:2005-14